The Manufacturers Life Insurance Company Reduces Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

The Manufacturers Life Insurance Company lessened its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 4.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 120,612 shares of the biotechnology company’s stock after selling 6,105 shares during the period. The Manufacturers Life Insurance Company owned about 0.05% of ADMA Biologics worth $2,068,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Oxford Asset Management LLP purchased a new position in shares of ADMA Biologics during the fourth quarter valued at approximately $230,000. Oberweis Asset Management Inc. raised its holdings in ADMA Biologics by 15.0% in the 4th quarter. Oberweis Asset Management Inc. now owns 3,342,560 shares of the biotechnology company’s stock worth $57,325,000 after purchasing an additional 435,480 shares in the last quarter. Voya Investment Management LLC lifted its position in shares of ADMA Biologics by 46.8% in the 4th quarter. Voya Investment Management LLC now owns 918,361 shares of the biotechnology company’s stock worth $15,750,000 after purchasing an additional 292,642 shares during the period. Harvest Investment Services LLC boosted its stake in shares of ADMA Biologics by 40.1% during the 4th quarter. Harvest Investment Services LLC now owns 125,867 shares of the biotechnology company’s stock valued at $2,159,000 after purchasing an additional 36,025 shares in the last quarter. Finally, Massar Capital Management LP purchased a new position in shares of ADMA Biologics during the fourth quarter valued at about $1,275,000. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Price Performance

ADMA stock opened at $19.99 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The firm has a 50 day moving average price of $20.23 and a 200-day moving average price of $18.74. ADMA Biologics, Inc. has a 52-week low of $8.42 and a 52-week high of $25.67. The firm has a market capitalization of $4.75 billion, a price-to-earnings ratio of 71.39 and a beta of 0.57.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The company had revenue of $114.80 million during the quarter, compared to the consensus estimate of $116.40 million. During the same period last year, the firm posted $0.08 earnings per share. The company’s revenue was up 40.2% compared to the same quarter last year. Equities research analysts forecast that ADMA Biologics, Inc. will post 0.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ADMA has been the subject of several research analyst reports. StockNews.com lowered shares of ADMA Biologics from a “hold” rating to a “sell” rating in a report on Friday. Raymond James lifted their price target on ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a research report on Thursday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $24.25.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.